Garry Fenton
Garry Fenton, Harlow GB
Patent application number | Description | Published |
---|---|---|
20090143437 | EP4 RECEPTOR ANTAGONISTS - Compounds of formula (X): | 06-04-2009 |
20090281069 | ORGANIC COMPOUNDS - The present invention relates to compounds of the formula; | 11-12-2009 |
20090298899 | EP2 RECEPTOR AGONISTS - The disclosure provides EP | 12-03-2009 |
20100261760 | EP2 Receptor Agonists - The disclosure provides EP2 receptor agonist compounds and methods for using the compounds for treating conditions which can be alleviated by agonism of an EP2 receptor. | 10-14-2010 |
20110034462 | ORGANIC COMPOUNDS - The present invention relates to compounds of the formula; and their use in therapy. | 02-10-2011 |
20130012485 | ORGANIC COMPOUNDS - Compounds of the formula (I) are provided: | 01-10-2013 |
Garry Fenton, Dagenham GB
Patent application number | Description | Published |
---|---|---|
20100240677 | Compounds as PDE IV and TNF Inhibitors - This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). | 09-23-2010 |
Garry Fenton, Essex GB
Patent application number | Description | Published |
---|---|---|
20080306117 | EP4 RECEPTOR ANTAGONISTS - A compound of formula (I): | 12-11-2008 |
20090192138 | COMPOUNDS - The invention provides novel deazaxanthine and deazahypoxanthine compounds. The compounds may be useful in the therapy of diseases and conditions in which dipeptidylpeptidase-IV (DPP-IV) is implicated. | 07-30-2009 |
20100130556 | EP2 RECEPTOR AGONISTS - A compound of formula (III): or a salt, solvate and chemically protected form thereof, wherein: R | 05-27-2010 |